The high expression of RANKL (Receptor activator of nuclear factor kappa-B ligand) is also intriguing given RANKL is known to stimulate osteoclastogenesis and targeting RANKL has been shown to reduce risk of osteoporosis and related skeletal events secondary to bone metastases [25]. Here, TNFSF11 is linked to osteoporosis.